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Cracow, Poland
Objectives The purpose of this study was to investigate whether omega-3 polyunsaturated fatty acids (PUFAs) are able to
modify platelet responsiveness to dual antiplatelet therapy in stable coronary artery disease patients undergoing
percutaneous coronary intervention (PCI).
Background Although previous studies have suggested antiplatelet properties of omega-3 polyunsaturated fatty acids, it is
unknown whether they can enhance platelet inhibition on standard aspirin and clopidogrel treatment.
Methods The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) study
was an investigator-initiated, prospective, single-center, double-blind, placebo-controlled, randomized study. Pa-
tients receiving standard dual antiplatelet therapy (aspirin 75 mg/day and clopidogrel 600 mg loading dose fol-
lowed by 75 mg/day) were randomly assigned to receive the addition of 1 g of omega-3 ethyl esters (n  33) or
placebo (n  30) for 1 month. Platelet function was measured serially by light transmission aggregometry
(adenosine diphosphate and arachidonic acid [AA] were used as agonists) and assessment of the phosphor-
ylation status of the vasodilator-stimulated phosphoprotein at baseline, 12 h, 3 to 5 days, and 30 days af-
ter randomization.
Results The P2Y12 reactivity index was significantly lower, by 22.2%, after 1 month of treatment with omega-3 polyun-
saturated fatty acids compared with placebo when used in addition to dual antiplatelet therapy (p  0.020).
Maximal platelet aggregation induced by 5 and 20 mol/l adenosine diphosphate was lower by 13.3% (p 
0.026) and 9.8% (p  0.029), respectively, after 1 month of treatment with omega-3 polyunsaturated fatty ac-
ids compared with placebo. Platelet aggregation after AA stimulation was low and did not change significantly
throughout the study. There were no cases of aspirin resistance during follow-up that was suggestive of good
compliance with the medication.
Conclusions The addition of omega-3 ethyl esters to the combination of aspirin and clopidogrel significantly potentiates
platelet response to clopidogrel after percutaneous coronary intervention. (J Am Coll Cardiol 2010;55:1671–8)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.080r
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ccepted November 2, 2009.esistance, partially associated with inadequate compliance
1). In contrast to aspirin, response to clopidogrel is more
ariable and the incidence of low responsiveness to the drug
s much higher (2,3). Clopidogrel hyporesponsiveness is
ssociated with poor compliance, gene polymorphisms,
ntrinsic high platelet reactivity, variability of the drug
etabolism, and various drug interactions (4,5). Patients
ho are nonresponders to clopidogrel, particularly those
aving persistent high on-treatment platelet reactivity to
denosine diphosphate (ADP), have been shown to be at
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The OMEGA-PCI Study April 20, 2010:1671–8higher risk of post-percutaneous
coronary intervention (PCI)
ischemic events (1,4,6,7).
There is no reliably docu-
mented method for overcoming
clopidogrel hyporesponsiveness
when noncompliance or drug in-
teractions have been excluded
(3,8–10). Because platelet inhi-
bition by clopidogrel is dose de-
pendent, an increase in either the
loading or the maintenance dose
results in enhanced responsive-
ness to the drug (3,7,8). Re-
cently, triple antiplatelet therapy
with the addition of cilostazol
as also been reported to improve the biological effects of
lopidogrel (9,10). The advantages of such therapies must
e weighed against the potential to increase the risk of
leeding.
Increased consumption of oily fish or supplementation
ith ethyl esters of omega-3 polyunsaturated fatty acids
PUFAs) is currently recommended for secondary preven-
ion of cardiovascular events, especially after acute myocar-
ial infarction (11). The mechanisms of the beneficial effect
f omega-3 PUFAs on cardiovascular disease are multifac-
orial and remain unclear. Both anticoagulant and antiplate-
et actions of omega-3 PUFAs have been described. The
ntiplatelet effect of omega-3 PUFAs was explored in the
980s and 1990s with inconsistent findings (12,13). Cur-
ently, it is not clear whether administration of omega-3
UFAs affects platelet reactivity in patients already treated
ith dual antiplatelet therapy after PCI or myocardial
UFAs are able to modify platelet responsiveness to dual
ntiplatelet therapy in stable coronary artery disease patients
ndergoing PCI.
ethods
ubjects. Consecutive patients with stable coronary artery
isease (age range 30 to 80 years) undergoing PCI with
tent implantation were eligible for the study. Exclusion
riteria were as follows: acute coronary syndrome, bleeding,
oncomitant chronic anticoagulant therapy, thienopyridine
se before enrollment, platelet count 100  109/l, serum
reatinine 177 mol/l (2 mg/dl), and liver injury (alanine
ransaminase level 1.5 times above the upper limit of the
eference range). Patients were advised against the use of
onsteroidal anti-inflammatory drugs.
The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI
o Modify Responsiveness to Dual Antiplatelet Therapy)
tudy was an investigator-initiated, prospective, single-
enter, double-blind, placebo-controlled, randomized study.
atients were eligible after elective coronary angiography
Fig. 1). All subjects self-reported regular intake of aspirin
Abbreviations
and Acronyms
AA  arachidonic acid
ADP  adenosine
diphosphate
PRI  P2Y12 reactivity
index
PCI  percutaneous
coronary intervention
PGE1  prostaglandin E1
PUFA  polyunsaturated
fatty acid
VASP  vasodilator-
stimulated phosphoproteinor at least 14 days. Clopidogrel in a 600-mg loading dose, oas given after blood collection for baseline measurements
2 h before PCI. Patients were then randomized in the 1:1
atio using computerized random-number generation by an
ndependent investigator on a double-blind basis to receive
5 mg clopidogrel once daily, 75 mg aspirin once daily, and
,000 mg omega-3 PUFAs once daily (Omacor, Pronova
iocare AS/Solvay Pharma, Warsaw, Poland) or 75 mg
lopidogrel once daily, 75 mg aspirin once daily, and
lacebo for 4 weeks (Fig. 1). Study medication was started
ogether with the clopidogrel loading dose and continued
aily thereafter. Omega-3 PUFAs were administered in a
reparation containing ethyl esters of 460 mg eicosapenta-
noic acid and 380 mg docosahexaenoic acid. Compliance
ith medication use was assessed from the number of
ablets returned at each visit in both groups. Patients were
rovided with aspirin and clopidogrel at discharge to ensure
ompliance. The last tablets were taken in the presence of an
nvestigator 2 to 4 h before blood sampling. Patients were
lso asked to comply with a diet recommended by European
ociety of Cardiology that encouraged increased consumption
f the oily fish (11).
Platelet function assessment was performed at 4 time
oints: before clopidogrel and study medication loading (I);
2 h after the loading dose and immediately before PCI (II);
to 5 days after PCI (III), and 1 month after randomization
IV) (Fig. 1). Laboratory assays were combined with clinical
valuation. The occurrence of both ischemic and bleeding
vents was recorded.
The study complied with the Guidelines of Good Clin-
cal Practice (GCP) of the International Conference on
armonisation (ICH) and was approved by the Ethics
ommittee of the Jagiellonian University. Each patient
rovided written informed consent before entering the
tudy.
nd points of the study and sample size calculation. The
rimary end point of the study was P2Y12 reactivity index
PRI) assessed 30 days after randomization (at study time
oint IV). Secondary end points of the study included PRI
t study time points II and III and maximal platelet
ggregation induced by 5 and 20 mol/l ADP and by 0.5
mol/l AA throughout the study.
We hypothesized that the addition of omega-3 PUFAs to
ual antiplatelet therapy compared with placebo would
esult in an absolute 10% reduction of the primary end point
f the study with an SD of the differences between the 2
roups of 16%. Choosing a power of 90% and a 2-sided
lpha level of 0.05, at least 29 patients in each group were
equired.
ample collection. Blood samples obtained from an ante-
ubital vein were immediately drawn to the tubes containing
.2% trisodium citrate. Samples were processed 30 to 60
in after blood collection.
ight transmission aggregometry. Blood-citrate Vacu-
ainer tubes were centrifuged at 120 g for 10 min to recover
latelet-rich plasma and subsequently centrifuged for an-
ther 10 min at 850 g to obtain platelet-poor plasma.
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April 20, 2010:1671–8 The OMEGA-PCI Studylatelets were stimulated with 0.5 mmol/l AA, and 5 and 20
mol/l ADP. Aggregation was measured with the
-channel Chronolog Aggregometer (Chrono-Log 490;
hrono-Log Corp., Haverton, Pennsylvania). Light trans-
ission was adjusted using platelet-rich plasma (PRP) to
epresent 0% and platelet-poor plasma (PPP) to represent
00% transmission for each measurement. Curves were
ecorded for 6 min. Platelet aggregation was expressed as
he maximal percentage of change in light transmission
rom baseline using platelet-poor plasma as reference.
RI. The PRI was calculated by assessment of the phos-
horylated status of vasodilator-stimulated phosphoprotein
VASP) according to standard protocols and a standardized
ssay (Platelet VASP, Biocytex Inc., Asnieres, France). The
nalyses were performed within 6 h after blood sampling. A
itrated blood sample was incubated with prostaglandin E1
PGE1) and PGE1  ADP for 10 min. Afterward, the
ample was fixed with paraformaldehyde and nonionic
etergent.
Quantitative flow cytometry (FACSCalibur System, BD
ioscience, Warsaw, Poland) was used with labeled mono-
lonal antibodies against serine 239-phosphorylated VASP,
ollowed by a secondary fluorescein isothiocyanate-
onjugated polyclonal goat anti-mouse antibody. The mean
Figure 1 Flow Diagram of the OMEGA-PCI Study
A prospective, randomized, double-blind, placebo-controlled study was undertaken
elective percutaneous coronary intervention (PCI). DHA  docosahexaenoic acid; Euorescence intensity of phosphorylated VASP levels after etimulation with PGE1 and PGE1  ADP was measured.
he PRI expressed as a percentage was then calculated
ccording to the formula: [(MFIPGE1) (MFIPGE1ADP)]/
MFIPGE1)  100%.
efinition of nonresponders to aspirin and clopidogrel.
spirin resistance was defined based on light transmission
ggregometry results (AA-induced aggregation 20%)
1,8). Clopidogrel responsiveness was defined as pre-
reatment minus post-treatment aggregation. Nonrespon-
iveness was characterized as having an absolute difference
etween baseline and post-treatment maximal aggregation
f 10% reduction with 5 mol/l ADP as the agonist (2).
When PRI was used to assess reactivity of the P2Y12
eceptor, patients with a PRI 69% were considered as low
esponders to clopidogrel (3).
enotyping. CYP2C19*2 (681GA, rs4244285) was
enotyped using a commercially available, validated Drug
etabolism Genotyping Assay (TaqMan MGB probes,
AM and VIC dye-labeled) and TaqMan Universal PCR
aster Mix with the Fast Real Time System 7900HT and
DS 2.3 software (all supplied by Applied Biosystems Inc.,
oster City, California).
tatistical analysis. All continuous variables were ex-
ressed as mean  SD, and categorical variables were
patients undergoing
eicosapentaenoic acid.in 63
PA xpressed as percentages. The Kolmogorov-Smirnov test
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The OMEGA-PCI Study April 20, 2010:1671–8as used to determine normal distribution. The nonpara-
etric Mann-Whitney U test was applied to compare both
ormally and non-normally distributed continuous variables
etween groups. The Wilcoxon signed rank test was used to
ssess continuous variables in each group separately at all
ime points of the study. The chi-square test, with or without
he Yates continuity correction, was used to evaluate the
ifferences in categorical variables between the respective study
roup when appropriate. All statistical tests were 2-sided.
tatistical significance was accepted at p  0.05. Statistical
nalysis was performed using the STATISTICA version 6.0
L software package (StatSoft, Inc., Tulsa, Oklahoma).
esults
emographics and clinical characteristics. Sixty-three
onsecutive patients (48 men and 15 women; age 63.1  10
ears) with stable coronary artery disease undergoing suc-
essful PCI with stent implantation were randomized (Fig.
). Baseline demographics, clinical characteristics, and con-
omitant medications of the randomized subjects are shown
n Table 1. There were no significant differences among
aseline variables, including genetic polymorphism of cyto-
hrome CYP2C19. During the study period, there were no
hanges in concomitant medications. During follow-up, no
ases of aspirin resistance were detected in both patient
roups based on light transmission aggregometry results.
ne patient in the placebo group and 1 patient in the
mega-3 PUFA group were not available for the final
latelet assessment, but no patients were lost to follow-up in
ither group.
dverse events. The adverse events that occurred during
he study were rated as mild, and their frequency did not
iffer significantly between groups. The number of patients
eporting minor bruising was similar in both groups (6
atients in the omega-3 PUFA group and 5 patients in the
lacebo group), and they did not require medical interven-
ion. There were no major cardiac adverse events during
-month follow-up in both groups.
latelet investigations. Platelet count was not different
etween groups at baseline and during follow-up (Table 2).
RI. The primary end point of the study—the PRI—was
ignificantly lower after 1 month of treatment with omega-3
thyl esters compared with placebo by 22.2% (95% confi-
ence interval: 2.93 to 21.87) (Fig. 2). Compared with
aseline, platelet aggregation assessed with PRI was de-
reased in both treatment arms at all time points of the
tudy. The primary end point of the study was significantly
ecreased compared with baseline values by 26.2% (p 
.0005) and 40.6% (p  0.0005) in the placebo and
mega-3 PUFA groups, respectively. At the end of follow-
p, there were 26.7% patients in the placebo group and
.1% in the omega-3 group who were determined to be low
esponders to clopidogrel based on the PRI (p  0.059).
latelet aggregometry. Compared with placebo, the addi-ion of omega-3 PUFAs to standard post-PCI dual anti- platelet therapy was associated with decreased maximal
latelet aggregation induced by 5 mol/l ADP after 1
onth of treatment by 13.3% (95% confidence interval:
.24 to 12.16) (Table 2). Similarly, in the omega-3 PUFA
roup compared with the placebo group, the maximal
latelet aggregation induced by 20 mol/l ADP was lower
fter 1 month by 9.8% (95% confidence interval: 0.67 to
0.33) (Fig. 3). Based on the results of light transmission
ggregometry after challenge with ADP, clopidogrel resis-
ance could be detected in 43.3% patients in the placebo
roup and 18.2% in the omega-3 PUFA group at the end of
he study (p  0.030).
Platelet aggregation after stimulation with AA was mark-
dly inhibited in both groups. There was 1 case of aspirin
esistance in the omega-3 PUFA group at baseline. After
ntroduction of the study treatment, that patient was no
onger resistant to aspirin. No cases of aspirin resistance
ere detected during follow-up in both groups of patients,
hich confirmed that patients were compliant with the
edication. At the end of the study, there was a trend
oward higher platelet inhibition after omega-3 PUFA
ersus placebo treatment that reached borderline signifi-
ance (p  0.094) (Table 2).
iscussion
ur study indicates that omega-3 PUFAs added to standard
ual antiplatelet therapy after PCI can influence platelet
esponse to clopidogrel based on the results of 2 assays
platelet aggregometry in PRP and VASP phosphorylation)
hat assess various pathways of platelet activation. Triple
herapy with aspirin, clopidogrel, and omega-3 PUFAs
ompared with standard dual antiplatelet therapy impaired
latelet aggregation when stimulated by ADP and decreased
ntracellular signaling from the P2Y12 receptor as assessed
y VASP phosphorylation. The relatively high on-
reatment platelet aggregation induced by ADP or assessed
y PRI observed in our study could be associated with a
igh prevalence of diabetes, hyperlipidemia, and abdominal
besity in our patients. In the cyclooxygenase pathway of
latelet activation, we found inhibited platelet aggregation
fter AA stimulation with a borderline effect of omega-3
UFAs.
We used 2 separate assays for platelet function assessment
ecause there is no consensually recommended test to
uantify platelet inhibition by clopidogrel. Lordkipanidzé
t al. (14) demonstrated recently that there is no strong
orrelation among various platelet function assays (aggre-
ometry, PFA-100, and VerifyNow P2Y12 [Accumetrics,
an Diego, California]). Light transmission aggregometry is
onsidered by many as the current gold standard in platelet
unction testing (14). Assessment of the phosphorylated
tatus of VASP has also been shown to correlate with
linical outcomes (3,6,7).
There have been several clinical studies in which it was
ossible to demonstrate an augmented effect of thienopyri-
1675JACC Vol. 55, No. 16, 2010 Gajos et al.
April 20, 2010:1671–8 The OMEGA-PCI StudyDemographics, Clinical Characteristics, and Concomitant MedicationsTable 1 Demographics, Clinical Characteristics, and Concomitant Medications
Placebo (n  30) Omega-3 (n  33) p Value
Age, yrs 63.8 9.4 62.4 9.7 0.550
Male 24 (80.0) 24 (72.7) 0.499
Risk factors
Hypertension 29 (96.7) 32 (97.0) 0.515
Hyperlipidemia 29 (96.7) 32 (97.0) 0.515
Diabetes 9 (30.0) 9 (27.3) 0.811
Metabolic syndrome 22 (73.3) 24 (72.7) 0.957
Waist circumference, cm 102.4 8.5 98.6 11.0 0.112
Body mass index, kg/m2 29.3 3.8 28.9 4.2 0.524
History of cigarette smoking 16 (53.3) 15 (45.5) 0.532
Active smoking 6 (20.0) 5 (15.2) 0.613
Family history 18 (60.0) 23 (69.7) 0.420
Medical history
Previous MI 12 (40.0) 9 (27.3) 0.285
Multivessel CAD 18 (60.0) 27 (81.8) 0.056
Previous PCI 7 (23.3) 5 (15.2) 0.409
Previous CABG 1 (3.3) 6 (18.2) 0.141
Previous stroke or PAD 11 (36.7) 8 (24.2) 0.283
Chronic kidney disease 10 (33.3) 5 (15.2) 0.091
Multivessel PCI 1 (3.3) 4 (12.1) 0.411
Lesion location
LAD 13 (43.3) 16 (48.5) 0.682
LCx 12 (40.0) 8 (24.2) 0.180
RCA 5 (16.7) 12 (36.4) 0.079
Reference vessel diameter, mm 3.1 0.5 3.2 0.5 0.367
Stent type
Bare-metal 23 (76.7) 23 (69.7) 0.534
Drug-eluting 7 (23.3) 10 (30.3) 0.534
No. of stents 1.3 0.6 1.3 0.5 0.912
Total stent length, mm 23.4 15.3 24.7 9.1 0.182
Periprocedural MI 4 (13.3) 3 (9.1) 0.894
Maximal troponin level, ng/ml 2.83 3.82 1.37 0.67 0.724
Medications
GP IIb/IIIa inhibitors 0 0 —
Beta-blocker 25 (83.3) 29 (87.9) 0.877
ACE inhibitors 27 (90.0) 28 (84.8) 0.815
ARB 2 (6.7) 7 (21.2) 0.198
Nitrates 12 (40.0) 14 (42.4) 0.845
Calcium antagonists 16 (53.3) 13 (39.4) 0.268
CYP3A4-metabolized statins 27 (90.0) 31 (93.9) 0.912
Non–CYP3A4-metabolized statins 0 0 —
Fibrates 2 (6.7) 0 0.431
Insulin 3 (10.0) 2 (6.1) 0.912
Proton pump inhibitors 8 (26.7) 8 (24.2) 0.825
Genotype distribution
G681A CYP2C19 polymorphism
GG 21 (70) 23 (69.7) 0.979
GA 9 (30) 9 (27.3) 0.811
AA 0 1 (3) 0.962
G allele frequency 51 (85) 55 (83.3) 0.798
Laboratory data
Glucose, mmol/l 5.7 1.8 5.1 0.7 0.186
Hemoglobin, g/dl, 14.3 1.3 14.1 1.3 0.882
WBCs, 109/l 7.15 1.62 7.36 2.02 0.563
Platelet count, 109/l 313.9 78.3 331.6 89.1 0.280
C-reactive protein, mg/l 2.06 1.56 2.09 1.52 0.337
Values are expressed as mean  SD or n (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; CABG  coronary artery bypass graft; CAD  coronary arterydisease; LAD  left anterior descending artery; LCx  left circumflex artery; MI  myocardial infarction; PAD  peripheral artery disease; PCI 
percutaneous coronary intervention; RCA  right coronary artery; WBC  white blood cell.
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The OMEGA-PCI Study April 20, 2010:1671–8ine treatment. It was demonstrated that adjusting the
lopidogrel loading dose, even above 600 mg according to
latelet monitoring using the PRI, might significantly
mprove the clinical outcome after PCI in clopidogrel-
esistant patients (7). Optimization of clopidogrel therapy
y increasing the clopidogrel maintenance dose was also
roven feasible (3,8). Recently, a concept of add-on oral
ntiplatelet therapy has been presented (9,11,15). Angiolillo
t al. (9) showed in 25 diabetic patients with coronary artery
isease receiving dual antiplatelet therapy that the PRI was
ignificantly lower by 39% (p  0.0002) after cilostazol
reatment compared with placebo. Shim et al. (10) demon-
trated in 400 patients undergoing PCI with drug-eluting
tent implantation that adding cilostazol to aspirin and
lopidogrel therapy decreased the prevalence of clopidogrel
esistance (VerifyNow System, Accumetrics) from 41.4% in
he placebo group to 26.5% in the triple antiplatelet therapy
roup (p  0.001). Recently, Chen et al. (16) demonstrated
hat adding cilostazol to standard dual antiplatelet therapy
esulted in the lower incidence of major adverse cardiac
vents in 8 months of follow-up in patients with acute
yocardial infarction undergoing primary PCI. In our
tudy, we demonstrated similar, although milder, effects on
latelet function profiles with omega-3 ethyl esters. Based
hanges in Platelet Count and Aggregationver Time in Plac bo and Omega-3 PUFA GroupsTable 2 Ch nges in Platelet Count and AggregationOver Time in Placebo and Omega-3 PUFA Groups
Platelet Studies
Group
p ValuePlacebo Omega-3 PUFAs
Platelet count, %
Baseline 313.8 78.0 331.6 88.5 0.275
12 h 317.6 108.9 353.1 105.3 0.098
3–5 days 314.5 98.4 294.8 71.3 0.561
1 month 327.1 110.6 357.1 86.5 0.371
PRI, %
Baseline 75.6 20.0 73.1 19.0 0.784
12 h 61.4 20.4 50.2 18.8 0.022
3–5 days 49.4 14.5 46.7 13.9 0.379
1 month 55.8 17.2 43.4 20.1 0.020
LTA ADP, 5 mol/l
Baseline 62.2 9.6 62.4 9.0 0.893
12 h 47.3 10.4 44.8 11.4 0.268
3–5 days 47.7 13.4 42.2 11.9 0.068
1 month 50.2 12.2 43.5 9.4 0.026
LTA ADP, 20 mol/l
Baseline 70.1 8.7 68.8 9.7 0.502
12 h 55.5 12.2 52.3 11.7 0.293
3–5 days 56.4 16.9 50.7 11.1 0.023
1 month 56.3 11.5 50.8 7.8 0.029
LTA AA, 5 mmol/l
Baseline 1.1 1.1 1.3 1.2 0.510
12 h 1.1 0.9 1.4 1.7 0.783
3–5 days 1.5 2.4 1.5 1.3 0.639
1 month 2.1 2.3 1.3 1.4 0.094
A  arachidonic acid; ADP  adenosine diphosphate; LTA  light transmission aggregometry;
RI  P2Y12 reactivity index; PUFAs  polyunsaturated fatty acids.n these results, it could be estimated that adding low-dosemega-3 PUFAs was responsible for 55% to 60% of the
ffect achieved with cilostazol demonstrated in the studies
y Angiolillo et al. (9) and Shim et al. (10). Conversely, the
ffectiveness of triple therapy with omega-3 PUFAs was
nly slightly weaker compared with aspirin/high-dose
Figure 2 Benefit of Omega-3 PUFAs on the
Primary End Point of the OMEGA-PCI Study
Patients in whom omega-3 polyunsaturated fatty acids (PUFAs) were added to
standard therapy with aspirin and clopidogrel had greater platelet inhibition
when assessed by the P2Y12 reactivity index (PRI) compared with placebo after
1 month of treatment. Error bars indicate SDs of the mean.
Figure 3 Maximal Platelet Aggregation Induced by 20 mol/l
ADP Over Time in the Placebo and Omega-3 Groups
Potentiated platelet response to clopidogrel after percutaneous coronary inter-
vention was demonstrated in patients receiving triple therapy with aspirin, clo-
pidogrel, and omega-3 polyunsaturated fatty acids compared with standard
dual antiplatelet therapy. Statistically significant maximal platelet aggregation
between placebo and omega-3 groups at each time point is indicated. ADP 
adenosine diphosphate.
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April 20, 2010:1671–8 The OMEGA-PCI Studylopidogrel maintenance therapy in the VASP-02 study
relative PRI reductions of 22.2% and 25.1%, respec-
ively) (3).
Omega-3 PUFAs have been known for their antiplatelet
nd anticoagulant effects, although in higher doses than
ere used in our study (12,13). Recently, Larson et al. (15)
emonstrated in 10 healthy volunteers using whole-blood
mpedance aggregometry that although omega-3 PUFAs
lone were not able to change platelet aggregation, they
acilitated aspirin-induced platelet inhibition. The mecha-
isms of favorable antithrombotic effects of omega-3 PUFAs are
omplex. It has been shown that alteration of fatty acid
omposition by omega-3 PUFA incorporation into platelet
embranes can alter not only membrane permeability, but
lso modulate function and activity of membrane receptors
nd transporters (12,13). Omega-3 PUFAs may also lower
hromboxane A2 production because epoxidation and hy-
roxylation of both AA and PUFAs are catalyzed by
ytochrome P-450 (17). Moreover, Engström et al. (18)
ound that fish oil administered with aspirin augments its
ffect by further decreasing thromboxane A2 production and
y counteracting the aspirin-induced unfavorable decrease
n circulating prostacyclin (prostaglandin I2) and increase in
eukotriene levels. Although the concept of more aggressive
ntiplatelet treatment based on the results of platelet func-
ion tests is feasible, the optimal degree of platelet inhibition
s unclear and must be confirmed in trials evaluating
ardiovascular outcomes and should be balanced with the
xcessive risk of bleeding (19). Omega-3 ethyl esters at a
ose that was tested in the OMEGA-PCI study have
reviously shown efficacy and a good safety profile in
atients after acute myocardial infarction (20) and patients
ith chronic heart failure (21). A 1-g dose of omega-3
UFAs has been previously considered not to affect blood
oagulation (12,13,15). The present study is the first to
ddress the concept of modifying antiplatelet response with
he addition of omega-3 ethyl esters to aspirin and clopi-
ogrel therapy in patients with stable coronary artery disease
ndergoing PCI.
tudy limitations. Because the present study was designed
nly to assess the effect on platelet responsiveness of adding
mega-3 PUFAs to standard post-PCI therapy, the sample
ize lacked statistical power to detect differences in clinical
utcomes. This issue was beyond the scope of the current
tudy.
It would be useful to perform concomitant platelet
embrane fluidity studies because lipophilic membranes
an be targeted by omega-3 PUFAs, thus improving re-
ponse to the antiplatelet drugs.
The dose of omega-3 PUFAs selected for the study was
ased on the applicability because it is recommended in
ardiovascular disease secondary prevention. Higher platelet
nhibition might be achieved with increased doses of
mega-3 PUFAs.onclusions
he addition of omega-3 ethyl esters to the standard dual
ntiplatelet therapy with aspirin and clopidogrel signifi-
antly potentiates platelet response to clopidogrel after PCI.
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